Table 1.

BRAF and NRAS mutations in melanoma specimens: relationship with time to progression

Patient no.	BRAF	NRAS	Time to progression while on 17-AAG (mo)
20	WT	G13D	49
24	V600E	WT	2
25	V600E	WT	1.5
26	WT	WT	1.5
27	V600E	WT	15
28	WT	WT	1

NOTE: Six patients with metastatic malignant melanoma were treated with 17-AAG at doses of 320 to 450 mg/m²/wk. The time to progression on treatment along with BRAF and NRAS mutation status are summarized.